SCHEMBL6859653

SCHEMBL6859653

C[C@H](NC(=O)/C=C/c1cc(F)cc(F)c1)c1cccc(-c2ccc(F)nc2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
ROCK2 O75116 2/20 0.43
LMNA P02545 2/20 0.42
KCNQ2 O43526 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
KCNQ3 O43525 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP19A1 P11511 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LIPG Q9Y5X9 1/20 0.39
PRKACA P17612 1/20 0.39
PRKACG P22612 1/20 0.39
PRKACB P22694 1/20 0.39
AKT1 P31749 1/20 0.39
ROCK1 Q13464 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859658 1.00 TDP1 (0.46) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL6859655 1.00 TDP1 (0.46) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL6859663 0.94 TDP1 (0.49) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL6859666 0.94 TDP1 (0.49) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL6859667 0.94 TDP1 (0.49) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL6625908 0.92 MEN1 (0.51) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL6625912 0.92 MEN1 (0.51) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL30794965 0.92 MEN1 (0.51) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL6625905 0.92 MEN1 (0.51) TDP1ROCK2LMNAKCNQ2CYP3A4
SCHEMBL6627707 0.91 TDP1 (0.59) TDP1ROCK2LMNAKCNQ2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831080-B2 E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents BRISTOL-MYERS SQUIBB COMPANY 2004-12-14 US disclosed